Literature DB >> 22520573

Inverted papilloma of the bladder: a review and an analysis of the recent literature of 365 patients.

Stefano Picozzi1, Stefano Casellato, Giorgio Bozzini, Dario Ratti, Alberto Macchi, Barbara Rubino, Gianna Pace, Luca Carmignani.   

Abstract

OBJECTIVES: Until the 1970s, inverted urothelial papilloma (IUP) of the bladder was generally regarded as a benign neoplasm. However, in the 1980s, several reported cases suggested the malignant potential of these papillomas, including cases with features indicative of malignancy, recurrent cases, and cases of IUP synchronous or metachronous with transitional cell carcinoma. The aim of this systematic review and analysis of the literature since 1990 to date is to contribute to unresolved issues regarding the biological behavior and prognosis of these neoplasms to establish some key points in the clinical and surgical management of IUP.
MATERIALS AND METHODS: Database searches yielded 109 references. Exclusion of irrelevant references left 10 references describing studies that fulfilled the predefined inclusion criteria.
RESULTS: One problem regarding these neoplasms is the difficulty of obtaining a correct histopathologic diagnosis. The main differential diagnosis is endophytic urothelial neoplasia, including papillary urothelial neoplasia of low malignant potential or urothelial carcinoma of low or high grade, while other considerably rare differential diagnoses include nephrogenic adenoma, paraganglioma, carcinoid tumor, cystitis cystica, cystitis glandularis, and Brunn's cell nests. The size of the lesions ranged from 1 to 50 mm (mean 12.8 mm). Most cases occurred in the fifth and sixth decade of life. The mean age of affected patients was 59.3 years (range 20-88 years). Analysis of the literature revealed a strong male predominance with a male/female ratio of 5.8:1. The most commonly reported sites of IUP were the bladder neck region and trigone. Of 285 cases included in 8 studies, 12 cases (4.2%) were multiple. Out of the total of 348 patients, 6 patients (1.72%) had a previous history of transitional cell carcinoma of the urinary bladder, 5 patients (1.43%) had synchronous transitional cell carcinoma of the urinary bladder, and 4 patients (1.15%) had subsequent transitional cell carcinoma of the urinary tract. The time before recurrence was <45 months (range 5-45 months, mean 27.7 months) after surgery.
CONCLUSIONS: Inverted papilloma could be considered a risk factor for transitional cell carcinoma, and it is clinically prudent to exclude transitional cell cancer when it is diagnosed. Follow-up is needed if the histologic diagnosis is definitive or doubtful. We recommend 4-monthly flexible cystoscopy for the first year and then every 6 months for the subsequent 3 years. Routine surveillance of the upper urinary tract in cases of inverted papilloma of the lower part of the urinary tract is not deemed necessary.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder; Cancer; Cystoscopy; Inverted papilloma; Transitional cell cancer; Urinary bladder

Mesh:

Year:  2012        PMID: 22520573     DOI: 10.1016/j.urolonc.2012.03.009

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  12 in total

Review 1.  Inverted urothelial papilloma: A review of diagnostic pitfalls and clinical management.

Authors:  Mary K Sweeney; Soroush Rais-Bahrami; Jennifer Gordetsky
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

2.  Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.

Authors:  Sumit Isharwal; Wenhuo Hu; Judy Sarungbam; Ying-Bei Chen; Anuradha Gopalan; Samson W Fine; Satish K Tickoo; Sahussapont J Sirintrapun; Sana Jadallah; Florence L Loo; Eugene J Pietzak; Eugene K Cha; Bernard H Bochner; Michael F Berger; Gopa Iyer; David B Solit; Victor E Reuter; Hikmat Al-Ahmadie
Journal:  J Pathol       Date:  2019-04-22       Impact factor: 7.996

Review 3.  The pathology of urinary bladder lesions with an inverted growth pattern.

Authors:  Aitao Guo; Aijun Liu; Xiaodong Teng
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

4.  Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities.

Authors:  Nima Almassi; Eugene J Pietzak; Judy Sarungbam; Satish K Tickoo; Victor E Reuter; David B Solit; Hikmat A Al-Ahmadie
Journal:  J Pathol       Date:  2020-02-28       Impact factor: 9.883

5.  Immunohistochemistry and Fluorescence In Situ Hybridization Can Inform the Differential Diagnosis of Low-Grade Noninvasive Urothelial Carcinoma with an Inverted Growth Pattern and Inverted Urothelial Papilloma.

Authors:  Juan-Juan Sun; Yong Wu; Yong-Ming Lu; Hui-Zhi Zhang; Tao Wang; Xiao-Qun Yang; Meng-Hong Sun; Chao-Fu Wang
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

6.  [Inverted papilloma of the bladder: a rare benign tumor: a case report].

Authors:  Hicham El Bote; Sihem Atik; Rami Fares; Ernest Hage
Journal:  Pan Afr Med J       Date:  2017-04-13

7.  Benign inverted papilloma at bladder neck causing acute urinary retention.

Authors:  Louisa Ho; Edward Jones; Alexander Kavanagh
Journal:  J Surg Case Rep       Date:  2018-06-15

8.  HRAS mutations are frequent in inverted urothelial neoplasms.

Authors:  Andrew S McDaniel; Yali Zhai; Kathleen R Cho; Saravana M Dhanasekaran; Jeffrey S Montgomery; Ganesh Palapattu; Javed Siddiqui; Todd Morgan; Ajjai Alva; Alon Weizer; Cheryl T Lee; Arul M Chinnaiyan; Michael J Quist; Catherine S Grasso; Scott A Tomlins; Rohit Mehra
Journal:  Hum Pathol       Date:  2014-06-18       Impact factor: 3.466

9.  A synchronous occurrence of urothelial carcinoma with abundant myxoid stroma and inverted papilloma of the urinary bladder.

Authors:  Kemal Behzatoğlu; Pelin Yildiz; Meltem Oznur; Erol R Bozkurt
Journal:  Rare Tumors       Date:  2012-09-14

10.  A case of bladder-inverted papilloma after brachytherapy for prostate cancer.

Authors:  Taisuke Ezaki; Takeo Kosaka; Shuji Mikami; Naoto Kaburaki; Ryuichi Mizuno; Mototsugu Oya
Journal:  Case Rep Nephrol Urol       Date:  2014-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.